Galectin therapeutics inc (GALT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Operating expenses:
Research and development

2,144

3,796

1,503

1,522

646

1,192

1,505

1,476

2,298

1,002

3,503

3,444

3,772

3,433

3,289

4,226

4,377

2,914

4,464

2,600

3,136

2,080

1,979

1,594

2,772

1,395

1,192

1,349

1,752

1,002

1,409

1,215

901

862

655

1,291

744

313

234

General and administrative

1,440

1,392

1,360

1,498

1,721

1,793

1,175

2,283

1,880

1,371

911

1,070

1,174

1,166

1,248

1,305

2,437

1,769

1,435

2,057

1,704

1,654

1,498

1,781

2,072

1,409

2,353

1,198

1,456

1,380

1,487

1,453

1,052

2,510

1,378

1,700

1,269

899

1,116

Total operating expenses

3,584

5,188

2,863

3,020

2,367

2,985

2,680

3,759

4,178

2,373

4,414

4,514

4,946

4,599

4,537

5,531

6,814

4,683

5,899

4,657

4,840

3,734

3,477

3,375

4,844

2,804

3,545

2,547

3,208

2,382

2,896

2,668

1,953

3,372

2,033

2,991

2,013

1,212

1,350

Total operating loss

-3,584

-5,188

-2,863

-3,020

-2,367

-2,985

-2,680

-3,759

-4,178

-2,373

-4,414

-4,514

-4,946

-4,599

-4,537

-5,531

-6,814

-4,683

-5,899

-4,657

-4,840

-3,734

-3,477

-3,375

-4,844

-2,804

-3,545

-2,547

-3,208

-2,382

-2,896

-2,668

-1,953

-3,372

-2,033

-2,991

-2,013

-1,212

-1,350

Other income (expense):
Interest income

50

73

101

43

14

15

15

4

4

3

6

6

9

8

11

12

14

12

12

14

14

13

12

13

4

5

3

3

5

6

7

8

3

4

5

4

5

3

1

Interest expense

22

22

22

21

22

80

87

85

84

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from equity method investment in Galectin Sciences, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10

-53

-67

-270

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-140

-384

100

-305

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

-

-

-

-

-

-

-

-

Total other income (expense)

28

51

79

22

-8

-65

-72

-81

-80

-9

6

6

9

8

11

12

14

12

12

14

14

3

-41

-54

-266

5

3

3

5

6

207

8

3

4

5

-136

-379

103

-304

Net loss

-3,556

-5,137

-2,784

-2,998

-2,375

-3,050

-2,752

-3,840

-4,258

-2,382

-4,408

-4,508

-4,937

-4,591

-4,526

-5,519

-6,800

-4,671

-5,887

-4,643

-4,826

-3,731

-3,518

-3,429

-5,110

-2,799

-3,542

-2,544

-3,203

-2,376

-2,689

-2,660

-1,950

-3,368

-2,028

-3,127

-2,392

-1,109

-1,654

Preferred stock dividends

-6

65

35

67

96

300

294

268

285

405

254

301

272

275

63

250

153

239

208

230

191

180

278

245

240

254

123

277

213

274

238

267

197

293

253

750

272

239

227

Warrant modification (Note 9)

-

0

0

0

6,622

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock accretion

-

-

-

-

-

-

-

-

-

-

-

-

-

2

56

58

57

57

57

58

57

57

57

57

58

58

58

57

56

58

58

57

57

57

58

57

58

551

594

Warrant modification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,763

-

-

-

-

-

-

-

-

-

-

-

Net loss applicable to common stockholders

-3,550

-5,202

-2,819

-3,065

-9,093

-3,350

-3,046

-4,108

-4,543

-2,787

-4,662

-4,809

-5,209

-4,868

-4,645

-5,827

-7,010

-4,967

-6,152

-4,931

-5,074

-3,968

-3,853

-3,731

-5,408

-3,111

-3,723

-11,641

-3,472

-2,708

-2,985

-2,984

-2,204

-3,718

-2,339

-3,934

-2,722

-1,899

-2,475

Net loss per common share — basic and diluted

-0.06

-0.30

0.05

0.06

-0.20

-0.68

0.07

0.11

0.12

-0.07

-0.13

-0.14

-0.15

-0.16

-0.16

-0.20

-0.24

-0.19

-0.26

-0.21

-0.22

-0.17

-0.17

-0.17

-0.27

-0.14

-0.22

-0.72

-0.22

-0.17

-0.19

-0.19

-0.17

-0.29

-0.19

-0.34

-0.24

-0.03

-0.05

Weighted average common shares outstanding — basic and diluted

56,956

57,045

56,631

50,301

44,975

41,224

40,921

38,227

37,284

38,299

35,165

34,692

33,928

29,732

29,282

29,023

28,827

25,894

23,793

23,731

23,062

23,092

22,051

21,983

20,270

18,193

16,988

16,236

16,079

15,982

15,822

15,710

13,010

-

12,353

11,590

-

-

-

Weighted average common shares outstanding - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,156

58,764

53,911